ReviewProstaglandins, leukotrienes, and essential fatty acids2011
Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease.
Review in Prostaglandins, leukotrienes, and essential fatty acids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Preliminary In Vitro Screening of Structure-Dependent β-Hydroxybutyrate Responses to Dietary Fatty Acids in Hepatocyte Models.Nutrients · 2026Article
- Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer's Disease.Cellular and molecular neurobiology · 2025Review
- Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach.Journal of Korean Neurosurgical Society · 2023Article
- Review
- Lipidomics of Bioactive Lipids in Alzheimer's and Parkinson's Diseases: Where Are We?International journal of molecular sciences · 2022Review
- Lipids and Alzheimer's Disease.International journal of molecular sciences · 2020Review
- A Perspective: Active Role of Lipids in Neurotransmitter Dynamics.Molecular neurobiology · 2020Review
- Ceramide regulates interaction of Hsd17b4 with Pex5 and function of peroxisomes.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2019Article
- Plasmalogens and Alzheimer's disease: a review.Lipids in health and disease · 2019Review
- An Exploratory Analysis of Potential New Biomarkers of Cognitive Function.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Is Grassfed Meat and Dairy Better for Human and Environmental Health?Frontiers in nutrition · 2019Article
- Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.Journal of neurology · 2014Review
- Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease.Frontiers in physiology · 2013Article
- The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival.Prostaglandins, leukotrienes, and essential fatty acids · 2013Review
- Neuroinflammation and proteostasis are modulated by endogenously biosynthesized neuroprotectin D1.Molecular neurobiology · 2012Review
- Lipidomics of Alzheimer's disease: current status.Alzheimer's research & therapy · 2012Article
- Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics.Metabolomics : Official journal of the Metabolomic SocietyArticle
- Brain investigation and brain conceptualization.Functional neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Preclinical and clinical evidence suggests that docosahexaenoic acid (DHA), an omega-3 fatty acid derived from diet or synthesized in the liver, decreases the risk of developing Alzheimer's disease (AD). DHA levels are reduced in the brain of subjects with AD, but it is still unclear whether human dementias are associated with dysregulations of DHA metabolism. A systems biological view of omega-3 fatty acid metabolism offered unexpected insights on the regulation of DHA homeostasis in AD [1]. Results of multi-organ lipidomic analyses were integrated with clinical and gene-expression data sets to develop testable hypotheses on the functional significance of lipid abnormalities observed and on their possible mechanistic bases. One surprising outcome of this integrative approach was the discovery that the liver of AD patients has a limited capacity to convert shorter chain omega-3 fatty acids into DHA due to a deficit in the peroxisomal d-bifunctional protein. This deficit may contribute to the decrease in brain DHA levels and contribute to cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.